Sandoz expands biosimilars business with Chinese biotech deal

Sandoz has signed a multi-million-dollar agreement with Chinese biotech company Shanghai Henlius Biotech, stepping up its expansion in biosimilars, the generic versions of complex biological medicines. The deal covers the development and commercialisation of up to ten so-called biosimilars. The agreement provides for payments totalling up to $322 million (CHF260 million), subject to the achievement of certain development and commercialisation milestones, Sandoz said on Monday. For the first…